Can a novel sleeping pill help Jingxin shed its generic label?
The pharmaceutical firm has gained traction with its first new drug and is seeking funds for further innovation, but its mainstay generics business is under pressure Key Takeaways: Jingxin Pharmaceutical…
Recent Articles
RELATED ARTICLES
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE -
CSPC Innovation pursues Hong Kong IPO as parent profits shrink
300765.SHE
-
Its revenue surging, can co-built fleets help Pony AI drive to profits?
2026.HKPONY.US
-
JBM Healthcare gets bitter pill from investors on anemic performance
2161.HK
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
- Insilico revenue soars above $100 million on AI drug partnerships
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
